<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00297115</url>
  </required_header>
  <id_info>
    <org_study_id>BY217/M2-125</org_study_id>
    <nct_id>NCT00297115</nct_id>
  </id_info>
  <brief_title>Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217/M2-125)</brief_title>
  <official_title>Effect of Roflumilast on Exacerbation Rate in Patients With COPD. The HERMES Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The aim of the study is to compare the effect of roflumilast on exacerbation rate and
      pulmonary function in patients with chronic obstructive pulmonary disease (COPD). Roflumilast
      will be administered orally once daily in the morning at one dose level. The study duration
      will be up to 56 weeks. The study will provide further data on safety and tolerability of
      roflumilast.

      For additional information (for US patients only) see www.COPDSTUDY.net or dial 866-788-2673
      (toll free).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1)</measure>
    <time_frame>Change from baseline over 52 weeks of treatment</time_frame>
    <description>Mean change from baseline during the treatment period in pre-bronchodilator FEV1 [L]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>COPD Exacerbation Rate (Moderate or Severe)</measure>
    <time_frame>52 weeks treatment period</time_frame>
    <description>Mean rate of COPD exacerbations requiring oral or parenteral glucocorticosteroids (=moderate COPD exacerbations), or requiring hospitalization, or leading to death (=severe COPD exacerbations), per patient per year. A COPD exacerbation is an event in the natural course of the disease characterized by a change in the patient's baseline dyspnea, cough and/or sputum beyond day-to-day variability sufficient to warrant a change in management [American Thoracic Society (ATS) / European Respiratory Society (ERS) 2005].</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-bronchodilator FEV1 [L]</measure>
    <time_frame>Change from baseline over 52 weeks of treatment</time_frame>
    <description>Mean change from baseline during the treatment period in post-bronchodilator FEV1 [L]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Mortality Due to Any Reason</measure>
    <time_frame>52 weeks treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Natural Log-transformed C-reactive Protein (CRP)</measure>
    <time_frame>Change from baseline to last post randomization measurement (52 weeks)</time_frame>
    <description>Mean change from baseline to the last post randomization measurement in natural log-transformed CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Transition Dyspnea Index (TDI) Focal Score During the Treatment Period</measure>
    <time_frame>Change from baseline over 52 weeks of treatment</time_frame>
    <description>The TDI is a recognized questionnaire to measure dyspnea in an out patient COPD population. At baseline, 3 components of dyspnea, each graded with 4 questions, were asked: - Functional Impairment - Magnitude of Task - Magnitude of Effort At each of the post-randomization visits questions from the TDI were asked related to 3 components: Change in - Functional Impairment - Magnitude of Task - Magnitude of Effort Each question in the TDI is graded from -3 (major deterioration) to +3 (major improvement). This results in a TDI Focal Score ranging from -9 to +9.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1568</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>Roflumilast</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>500 mcg, once daily, oral administration in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Roflumilast</intervention_name>
    <description>500 mcg, once daily, oral administration in the morning</description>
    <arm_group_label>Roflumilast</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  COPD patients having at least one exacerbation within last year

          -  FEV1/FVC ratio (post-bronchodilator) ≤ 70%

          -  FEV1 (post-bronchodilator) ≤ 50% of predicted

        Main Exclusion Criteria:

          -  COPD exacerbation not resolved at first baseline visit

          -  Diagnosis of asthma and/or other relevant lung disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AstraZeneca AstraZeneca</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Bayou La Batre</city>
        <state>Alabama</state>
        <zip>36509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Bullhead City</city>
        <state>Arizona</state>
        <zip>85442</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Fort Smith</city>
        <state>Arkansas</state>
        <zip>72917</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Carlsbad</city>
        <state>California</state>
        <zip>92008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Lakewood</city>
        <state>California</state>
        <zip>90712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Los Alamitos</city>
        <state>California</state>
        <zip>90720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95678</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95831</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Sepulveda</city>
        <state>California</state>
        <zip>91343</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <zip>95207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>6708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Deland</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Ormand Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>33127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <zip>33321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <zip>32960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Blue Ridge</city>
        <state>Georgia</state>
        <zip>30513</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Ft. Gordon</city>
        <state>Georgia</state>
        <zip>30905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Rincon</city>
        <state>Georgia</state>
        <zip>594</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Twin Falls</city>
        <state>Idaho</state>
        <zip>83301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Champaign</city>
        <state>Illinois</state>
        <zip>61820</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Elk Grove Village</city>
        <state>Illinois</state>
        <zip>60007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>North Chicago</city>
        <state>Illinois</state>
        <zip>60064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>River Forest</city>
        <state>Illinois</state>
        <zip>60305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Elkhart</city>
        <state>Indiana</state>
        <zip>46514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46254</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Dubuque</city>
        <state>Iowa</state>
        <zip>52001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Fort Dodge</city>
        <state>Iowa</state>
        <zip>50501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Waterloo</city>
        <state>Iowa</state>
        <zip>50702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Olathe</city>
        <state>Kansas</state>
        <zip>66061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Campbellsville</city>
        <state>Kentucky</state>
        <zip>42718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Hazard</city>
        <state>Kentucky</state>
        <zip>41701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>West Monroe</city>
        <state>Louisiana</state>
        <zip>71291</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <zip>21044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Brighton</city>
        <state>Michigan</state>
        <zip>48114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Interlochen</city>
        <state>Michigan</state>
        <zip>49643</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Livonia</city>
        <state>Michigan</state>
        <zip>48152</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Portage</city>
        <state>Michigan</state>
        <zip>49002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <zip>48602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Jefferson City</city>
        <state>Missouri</state>
        <zip>65101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Kansas City (-1453)</city>
        <state>Missouri</state>
        <zip>64106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Sunset</city>
        <state>Missouri</state>
        <zip>70584</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Bozeman</city>
        <state>Montana</state>
        <zip>59718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Absecon</city>
        <state>New Jersey</state>
        <zip>08201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>New Jersey</state>
        <zip>08610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>South Bound Brook</city>
        <state>New Jersey</state>
        <zip>08880</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Camillus</city>
        <state>New York</state>
        <zip>13031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Corning</city>
        <state>New York</state>
        <zip>14830</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Cortland</city>
        <state>New York</state>
        <zip>13045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Sylvania</city>
        <state>Ohio</state>
        <zip>43560</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Stoneboro</city>
        <state>Pennsylvania</state>
        <zip>16153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Swarthmore</city>
        <state>Pennsylvania</state>
        <zip>19081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Johnston</city>
        <state>Rhode Island</state>
        <zip>2919</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Union</city>
        <state>South Carolina</state>
        <zip>29379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Williamston</city>
        <state>South Carolina</state>
        <zip>29697</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Johnson City</city>
        <state>Tennessee</state>
        <zip>37604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38163</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>New Tazewell</city>
        <state>Tennessee</state>
        <zip>37825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Boerne</city>
        <state>Texas</state>
        <zip>78006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Corsicana</city>
        <state>Texas</state>
        <zip>75110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Hurst</city>
        <state>Texas</state>
        <zip>76054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <zip>75069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Seguin</city>
        <state>Texas</state>
        <zip>78155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Glendale</city>
        <state>Wisconsin</state>
        <zip>53212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Glendale</city>
        <state>Wisconsin</state>
        <zip>53217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3C 3P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5C 0A3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Spruce Grove</city>
        <state>Alberta</state>
        <zip>T7X 2Z8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Burnaby</city>
        <state>British Columbia</state>
        <zip>V5G 1T4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Penticton</city>
        <state>British Columbia</state>
        <zip>V2A 5C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Truro</city>
        <state>Nova Scotia</state>
        <zip>B2N 1L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Chatham</city>
        <state>Ontario</state>
        <zip>N7M 1R2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8M 1K7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N5Y 5K7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5M 2V8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <zip>N7T 4X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Scarborough</city>
        <state>Ontario</state>
        <zip>M1B 4Z8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5S 2A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1V 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3S 2W1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <zip>G1V4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 4J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>St. Romuald</city>
        <state>Quebec</state>
        <zip>G6W 5M6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Ste-Foy</city>
        <state>Quebec</state>
        <zip>G1W 4R4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Antigonish</city>
        <zip>B2G2C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Bridgewater</city>
        <zip>B4V3N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Calgary</city>
        <zip>T1Y6J4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Corunna</city>
        <zip>N0N1G0</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <zip>T5N4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Fort Erie</city>
        <zip>L2A1Z3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Grimsby</city>
        <zip>L3M1P3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <zip>L8N3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Longueuil</city>
        <zip>J4N1E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Montreal</city>
        <zip>H2L2W5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Ontario</city>
        <zip>L2R2Z9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Richmond Hill</city>
        <zip>L4C2N9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Saint John</city>
        <zip>E3M3W5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Sherbrooke</city>
        <zip>J1H5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>St Jerome</city>
        <zip>J7Z5T3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>St Leonard</city>
        <zip>H1S3A9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Toronto</city>
        <zip>M5G1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Winnipeg</city>
        <zip>R2K3S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10559</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10717</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10965</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10969</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12165</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13507</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13597</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Donaustauf</city>
        <zip>93093</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Großhansdorf</city>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Halle</city>
        <zip>6108</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20535</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Landsberg/Lech</city>
        <zip>86899</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Neuruppin</city>
        <zip>16816</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Oschersleben</city>
        <zip>39387</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Potsdam</city>
        <zip>14464</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Potsdam</city>
        <zip>14467</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Regensburg</city>
        <zip>93059</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Rüdersdorf</city>
        <zip>15562</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Ulm</city>
        <zip>89073</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Bangalore, Karnataka</city>
        <zip>560 029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <zip>560 002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <zip>560 034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Chennai</city>
        <zip>600 034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Coimbatore, Tamilnadu</city>
        <zip>641 044</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Coimbatore</city>
        <zip>641 004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Coimbatore</city>
        <zip>641 014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Goa</city>
        <zip>403 002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Hyderabad</city>
        <zip>12</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Indore, South Tukuganj</city>
        <zip>452001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Mangalore</city>
        <zip>574 160</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Mangalore</city>
        <zip>575 001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Mumbai, Byculla</city>
        <zip>400 008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Mumbai, Dadar (E)</city>
        <zip>400 014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Mumbai</city>
        <zip>400022</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Mysore</city>
        <zip>570004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Nagpur</city>
        <zip>440 012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Nagpur</city>
        <zip>440 013</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Nagpur</city>
        <zip>440012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Pune</city>
        <zip>411 014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Pune</city>
        <zip>411033</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Shastri Nagar, Jaipur</city>
        <zip>302 016</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Bergamo</city>
        <zip>24100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Bologna</city>
        <zip>40136</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Cassano Murge</city>
        <zip>70020</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Milano</city>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Parma</city>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Roma</city>
        <zip>135</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Trieste</city>
        <zip>34100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Verona</city>
        <zip>37100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Veruno</city>
        <zip>28010</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Chrzanów</city>
        <zip>32500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Czestochowa</city>
        <zip>42200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Dzialdowo</city>
        <zip>13-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-752</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Kraków</city>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Kraków</city>
        <zip>31202</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-718</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Poznan</city>
        <zip>60-569</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Warsawa</city>
        <zip>01-138</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>1140</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Wodzislaw Slaski</city>
        <zip>44300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Zgierz</city>
        <zip>95100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Bellville, Cape Town</city>
        <zip>7530</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Berea, Durban</city>
        <zip>4000</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>C/O Netcare &amp; Garsfontein Roads</city>
        <zip>44</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Cape Town, Tygerberg</city>
        <zip>7505</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <zip>7764</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <zip>8001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Durban, Amanzimtoti</city>
        <zip>4126</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Durbanville / Cape Town</city>
        <zip>7550</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Mowbray, Cape Town</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Paarl, Cape Town</city>
        <zip>7626</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <zip>181</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Somerset West</city>
        <zip>7130</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Badajoz</city>
        <zip>6080</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Calde (Lugo)</city>
        <zip>27210</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Cartagena</city>
        <zip>30203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Elda</city>
        <zip>3600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Getafe</city>
        <zip>28905</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Guadalajara</city>
        <zip>19002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Merida (Badajoz)</city>
        <zip>6800</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Partida de Bacarot (Alicante)</city>
        <zip>3114</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Pontevedra</city>
        <zip>36071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Requena</city>
        <zip>46340</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Talavera de la Reina (Toledo)</city>
        <zip>45600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Tarrasa (Barcelona)</city>
        <zip>8221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Toldeo</city>
        <zip>45004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed Investigational Site</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>India</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ; M2-124 and M2-125 study groups. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009 Aug 29;374(9691):685-94. doi: 10.1016/S0140-6736(09)61255-1. Erratum in: Lancet. 2010 Oct 2;376(9747):1146.</citation>
    <PMID>19716960</PMID>
  </results_reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2006</study_first_submitted>
  <study_first_submitted_qc>February 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2006</study_first_posted>
  <results_first_submitted>March 17, 2011</results_first_submitted>
  <results_first_submitted_qc>April 20, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 19, 2011</results_first_posted>
  <last_update_submitted>October 3, 2016</last_update_submitted>
  <last_update_submitted_qc>October 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Roflumilast</keyword>
  <keyword>COPD</keyword>
  <keyword>Chronic obstructive pulmonary disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Roflumilast</title>
          <description>500 mcg, once daily, oral administration in the morning</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="772">Includes all randomized patients who took at least one dose of the investigational drug.</participants>
                <participants group_id="P2" count="796">Includes all randomized patients who took at least one dose of the investigational drug.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="527"/>
                <participants group_id="P2" count="550"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="245"/>
                <participants group_id="P2" count="246"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Roflumilast</title>
          <description>500 mcg, once daily, oral administration in the morning</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>once daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="772"/>
            <count group_id="B2" value="796"/>
            <count group_id="B3" value="1568"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.92" spread="9.2"/>
                    <measurement group_id="B2" value="64.31" spread="9.0"/>
                    <measurement group_id="B3" value="64.12" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="162"/>
                    <measurement group_id="B2" value="148"/>
                    <measurement group_id="B3" value="310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="610"/>
                    <measurement group_id="B2" value="648"/>
                    <measurement group_id="B3" value="1258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1)</title>
        <description>Mean change from baseline during the treatment period in pre-bronchodilator FEV1 [L]</description>
        <time_frame>Change from baseline over 52 weeks of treatment</time_frame>
        <population>ITT (Intention to Treat) analysis. Number of participants analyzed = number of participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast</title>
            <description>500 mcg, once daily, oral administration in the morning</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1)</title>
          <description>Mean change from baseline during the treatment period in pre-bronchodilator FEV1 [L]</description>
          <population>ITT (Intention to Treat) analysis. Number of participants analyzed = number of participants with data available.</population>
          <units>mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="730"/>
                <count group_id="O2" value="766"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" spread="7"/>
                    <measurement group_id="O2" value="-25" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>No adjustment of the significance level was done as a hierarchical approach for hypotheses testing was used.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Repeated measurements analysis (change from baseline over 52 weeks of treatment taking all post-randomization measurements into account).</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>58</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>41</ci_lower_limit>
            <ci_upper_limit>75</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>COPD Exacerbation Rate (Moderate or Severe)</title>
        <description>Mean rate of COPD exacerbations requiring oral or parenteral glucocorticosteroids (=moderate COPD exacerbations), or requiring hospitalization, or leading to death (=severe COPD exacerbations), per patient per year. A COPD exacerbation is an event in the natural course of the disease characterized by a change in the patient’s baseline dyspnea, cough and/or sputum beyond day-to-day variability sufficient to warrant a change in management [American Thoracic Society (ATS) / European Respiratory Society (ERS) 2005].</description>
        <time_frame>52 weeks treatment period</time_frame>
        <population>ITT analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast</title>
            <description>500 mcg, once daily, oral administration in the morning</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>once daily</description>
          </group>
        </group_list>
        <measure>
          <title>COPD Exacerbation Rate (Moderate or Severe)</title>
          <description>Mean rate of COPD exacerbations requiring oral or parenteral glucocorticosteroids (=moderate COPD exacerbations), or requiring hospitalization, or leading to death (=severe COPD exacerbations), per patient per year. A COPD exacerbation is an event in the natural course of the disease characterized by a change in the patient’s baseline dyspnea, cough and/or sputum beyond day-to-day variability sufficient to warrant a change in management [American Thoracic Society (ATS) / European Respiratory Society (ERS) 2005].</description>
          <population>ITT analysis.</population>
          <units>exacerbations per patient per year</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="772"/>
                <count group_id="O2" value="796"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.210" lower_limit="1.074" upper_limit="1.364"/>
                    <measurement group_id="O2" value="1.485" lower_limit="1.333" upper_limit="1.655"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0035</p_value>
            <p_value_desc>No adjustment of the significance level was done as a hierarchical approach for hypotheses testing was used.</p_value_desc>
            <method>Poisson regression</method>
            <param_type>Rate ratio</param_type>
            <param_value>0.815</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.057</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.710</ci_lower_limit>
            <ci_upper_limit>0.935</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-bronchodilator FEV1 [L]</title>
        <description>Mean change from baseline during the treatment period in post-bronchodilator FEV1 [L]</description>
        <time_frame>Change from baseline over 52 weeks of treatment</time_frame>
        <population>ITT analysis. Number of participants analyzed = number of participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast</title>
            <description>500 mcg, once daily, oral administration in the morning</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Post-bronchodilator FEV1 [L]</title>
          <description>Mean change from baseline during the treatment period in post-bronchodilator FEV1 [L]</description>
          <population>ITT analysis. Number of participants analyzed = number of participants with data available.</population>
          <units>mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="724"/>
                <count group_id="O2" value="764"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44" spread="7"/>
                    <measurement group_id="O2" value="-17" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>No adjustment of the significance level was done as a hierarchical approach for hypotheses testing was used.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Repeated measurements analysis (change from baseline over 52 weeks of treatment taking all post-randomization measurements into account).</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>61</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>44</ci_lower_limit>
            <ci_upper_limit>79</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Mortality Due to Any Reason</title>
        <time_frame>52 weeks treatment period</time_frame>
        <population>ITT analysis. Number of participants analyzed = number of participants who died.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast</title>
            <description>500 mcg, once daily, oral administration in the morning</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Mortality Due to Any Reason</title>
          <population>ITT analysis. Number of participants analyzed = number of participants who died.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="201.0" spread="116.9"/>
                    <measurement group_id="O2" value="214.6" spread="137.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5028</p_value>
            <p_value_desc>No adjustment of the significance level was done as a hierarchical approach for hypotheses testing was used.</p_value_desc>
            <method>Cox proportional hazards regression</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.213</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.350</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.689</ci_lower_limit>
            <ci_upper_limit>2.137</ci_upper_limit>
            <estimate_desc>The statistical analysis is based on the ITT Analysis Set (n= 772 in the roflumilast group, n= 796 in the placebo group).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Natural Log-transformed C-reactive Protein (CRP)</title>
        <description>Mean change from baseline to the last post randomization measurement in natural log-transformed CRP</description>
        <time_frame>Change from baseline to last post randomization measurement (52 weeks)</time_frame>
        <population>ITT analysis. Number of participants analyzed = number of participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast</title>
            <description>500 mcg, once daily, oral administration in the morning</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Natural Log-transformed C-reactive Protein (CRP)</title>
          <description>Mean change from baseline to the last post randomization measurement in natural log-transformed CRP</description>
          <population>ITT analysis. Number of participants analyzed = number of participants with data available.</population>
          <units>mg/L</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="680"/>
                <count group_id="O2" value="696"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0840" lower_limit="0.9766" upper_limit="1.2033"/>
                    <measurement group_id="O2" value="1.0233" lower_limit="0.9228" upper_limit="1.1348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3627</p_value>
            <p_value_desc>No adjustment of the significance level was done as a hierarchical approach for hypotheses testing was used.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model including last observation carried forward (LOCF) method</method_desc>
            <param_type>Mean Difference calculated as ratio</param_type>
            <param_value>1.0593</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9356</ci_lower_limit>
            <ci_upper_limit>1.1994</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Transition Dyspnea Index (TDI) Focal Score During the Treatment Period</title>
        <description>The TDI is a recognized questionnaire to measure dyspnea in an out patient COPD population. At baseline, 3 components of dyspnea, each graded with 4 questions, were asked: - Functional Impairment - Magnitude of Task - Magnitude of Effort At each of the post-randomization visits questions from the TDI were asked related to 3 components: Change in - Functional Impairment - Magnitude of Task - Magnitude of Effort Each question in the TDI is graded from –3 (major deterioration) to +3 (major improvement). This results in a TDI Focal Score ranging from –9 to +9.</description>
        <time_frame>Change from baseline over 52 weeks of treatment</time_frame>
        <population>ITT analysis. Number of participants analyzed = number of participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast</title>
            <description>500 mcg, once daily, oral administration in the morning</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Transition Dyspnea Index (TDI) Focal Score During the Treatment Period</title>
          <description>The TDI is a recognized questionnaire to measure dyspnea in an out patient COPD population. At baseline, 3 components of dyspnea, each graded with 4 questions, were asked: - Functional Impairment - Magnitude of Task - Magnitude of Effort At each of the post-randomization visits questions from the TDI were asked related to 3 components: Change in - Functional Impairment - Magnitude of Task - Magnitude of Effort Each question in the TDI is graded from –3 (major deterioration) to +3 (major improvement). This results in a TDI Focal Score ranging from –9 to +9.</description>
          <population>ITT analysis. Number of participants analyzed = number of participants with data available.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="729"/>
                <count group_id="O2" value="769"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.662" spread="0.087"/>
                    <measurement group_id="O2" value="0.376" spread="0.084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0059</p_value>
            <p_value_desc>No adjustment of the significance level was done as a hierarchical approach for hypotheses testing was used.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Repeated measurements analysis (change from baseline over 52 weeks of treatment taking all post-randomization measurements into account).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.286</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.104</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.082</ci_lower_limit>
            <ci_upper_limit>0.489</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>52 weeks treatment period</time_frame>
      <desc>The Safety Set was based on all randomized patients who took at least one dose of the investigational drug after randomization. Six patients randomized to placebo received roflumilast instead and were included in the roflumilast group for safety analyses.</desc>
      <group_list>
        <group group_id="E1">
          <title>Roflumilast</title>
          <description>500 mcg, once daily, oral administration in the morning</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>once daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="157" subjects_at_risk="778"/>
                <counts group_id="E2" subjects_affected="183" subjects_at_risk="790"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Polycythaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="778"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="778"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="778"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="778"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Cor pulmonale</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Mitral valve stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Supraventricular tachyarrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Intestinal polyp</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Pancreatic cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Metaplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anti-neutrophil cytoplasmic antibody positive vasculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="778"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Pneumonia primary atypical</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Comminuted fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Eye penetration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Foreign body trauma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Plasmacytoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Adenoma benign</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Carcinoid tumour of the small bowel</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Gastric cancer stage II</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Metastasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Metastatic carcinoma of the bladder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Neuroendocrine carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Oesophageal neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer stage unspecified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Anoxic encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Hypoxic encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Optic neuritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Wernicke's encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Micturition disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="110" subjects_affected="87" subjects_at_risk="778"/>
                <counts group_id="E2" events="160" subjects_affected="121" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="778"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="778"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Hypoventilation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Respiratory acidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Leukocytoclastic vasculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Coronary artery bypass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Endarterectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="778"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
              <event>
                <sub_title>Peripheral artery aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="778"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="790"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="145" subjects_at_risk="778"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="790"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <description>non-serious</description>
                <counts group_id="E1" events="71" subjects_affected="64" subjects_at_risk="778"/>
                <counts group_id="E2" events="25" subjects_affected="23" subjects_at_risk="790"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="43" subjects_affected="35" subjects_at_risk="778"/>
                <counts group_id="E2" events="57" subjects_affected="47" subjects_at_risk="790"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="67" subjects_affected="65" subjects_at_risk="778"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="790"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The study results may be published and/or presented at scientific meetings. Prior to any submission, all manuscripts/abstracts must be presented to the sponsor for possible comments.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>AstraZeneca Clinical Study Information Center</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>1-877-240-9479</phone>
      <email>information.center@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

